Traders should monitor FDA feedback on the Lucid-MS IND and any subsequent Phase 2 trial initiation. The imaging data de-risks the biomarker strategy but remains early-stage; watch for next data readouts from the MGH study.
Price Chart
Executive Summary
Quantum BioPharma announced that its collaborative imaging study with Massachusetts General Hospital has reached the midpoint of patient enrollment, with encouraging preliminary PET imaging data showing robust signal in acute MS lesions. This milestone supports the potential of the [F]3F4AP PET tracer as a biomarker for demyelination, which could aid development of the company's lead candidate Lucid-MS, currently in Phase 2 IND review by the FDA.
Key Facts
- Patient enrollment in the MGH imaging study has reached the halfway mark.
- Preliminary imaging data show robust signal in acute MS lesions and potential sensitivity to gray matter lesions.
- The PET tracer [F]3F4AP is being validated as a biomarker for demyelination and myelin repair.
- Lucid-MS (Lucid-21-302) targets PAD2 to prevent and reverse myelin degradation in preclinical models.
- IND submission for Phase 2 trial of Lucid-MS was submitted to the FDA in March 2026.
- Quantum retains 19.84% of Unbuzzd and a 7% royalty on sales until $250 million, then 3% in perpetuity.
Financial Impact
No financial figures disclosed; market cap is $44M. The imaging milestone is a non-financial catalyst that could de-risk Lucid-MS development.
Risk Factors
- Preliminary imaging results may not replicate in larger cohorts.
- FDA may not approve the IND or may require additional studies.
- Company may need additional financing to complete development.
- Lucid-MS is still in early clinical stages with no approved product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003495 |
| Document: f6k_051826.htm | 0001171843-26-003495 |
| Document: 0001171843-26-003495-index-headers.html | 0001171843-26-003495 |
| Document: 0001171843-26-003495-index.html | 0001171843-26-003495 |
| Document: 0001171843-26-003495.txt | 0001171843-26-003495 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers